ClinicalTrials.gg
WithdrawnNCT06666335Updated Jun 29, 2026

A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF

A Phase 4 interventional study of Anakinra in Familial Mediterranean Fever (FMF ), sponsored by Swedish Orphan Biovitrum. Withdrawn. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Swedish Orphan Biovitrum · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Business decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of anakinra in Chinese patients with colchicine-resistand Familial Mediterranian Fever (FMF). The study consists of up to one month screening, to see if a patient is suitable to the study, 6 months of treatment with anakinra and one month safety follow up after last dose of anakinra. In total 3 patients, male and female from 2 years of age (minimum 10kg weight), will be enrolled to the study.

Read the detailed description

This is a prospective, open-label, single-arm, multi-center study, and this study consists of a 6-month treatment period with anakinra followed by a 4-Week period to evaluate safety of anakinra after the last dose of study drug i.e. at Month 7. The study is divided into three parts: screening, treatment period, and safety follow-up.

The patient will enter screening after informed consent is obtained and will undergo screening assessments to confirm eligibility. Duration of the screening period will be kept as short as possible and should not exceed 4 weeks.

Patients will be assigned to study drug after they have met all of the inclusion criteria and none of the exclusion criteria. Patients will receive daily subcutaneous treatment with anakinra for 6 months.

After the last dose of anakinra at Month 6, the safety will continue to be evaluated at a Safety Follow-up visit., at Month 7.

The primary endpoint will be change in the number of FMF attacks per month per patient from baseline to subsequent study visits, up to Month 6.

02

Conditions studied

  • Familial Mediterranean Fever (FMF )
03

In context

Familial Mediterranean Fever

61 studies on the registry are indexed under Familial Mediterranean Fever; 27 are open to participants now.

Browse Familial Mediterranean Fever studies →

Lead sponsor

Swedish Orphan Biovitrum is the lead sponsor of 82 studies on the registry; 6 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. form signed by the patient or a legal guardian representative.
  2. Male or female patients, 2 years of age or older with a body weight ≥ 10 kg.
  3. Diagnosis of FMF confirmed by a positive genetic testing i.e., mutations in both alleles of the MEFV gene (i.e. homozygous or compound heterozygous).
  4. Patient must have an estimated mean of at least 2 acute FMF attacks per month within 2 months prior to enrollment to the study.
  5. Patient must be resistant to colchicine treatment.
  6. Female patients of and male patients with female partners of childbearing potential must use an effective method of during the study (abstinence being a possible option) as well as a negative pregnancy test prior to enrollment for females of childbearing potential and participating in the study.
  7. Negative tuberculosis screening confirmed at screening visit by the Mantoux Tuberculin skin test (TST) using purified protein derivative (PPD), or by Interferon-Gamma-Release Assays (IGRAs) e.g., QuantiFERON® TB Gold Plus (QFT-Plus) or T-Spot® (TB Test) within 8 weeks prior to enrollment. Negative results must be complemented by the medical history, physical examination, and Chest X-Ray. Patients presenting positive TST or IGRA with or without active or clinical suspicion of latent tuberculosis are not eligible to enter the study. Previously vaccinated for Tuberculosis patients: IGRA positive patients are not eligible to enter the study; TST positive patients with an induration of 15 mm and more are also not eligible to enter the study, TST positive patients (with an induration up to 15 mm) are also not eligible to enter the study, unless an IGRA test is subsequently performed and provides a negative result.

Exclusion criteria

Exclusion Criteria:

  1. Previous enrollment to this study.
  2. Participation in another clinical interventional study 30 days prior to enrollment.
  3. Treatment with an drug within 5 half-lives prior to enrollment.
  4. Previous or current treatment with anakinra, or any other IL-1 inhibitor.

6. within 4 weeks prior to enrollment.

7. Known presence or suspicion of active, chronic or recurrent bacterial, fungal or viral infections, including but not limited to tuberculosis, infection, Covid-19 infection, or C infection at baseline.

8. Clinical evidence of liver disease or liver injury as indicated by presence of abnormal liver tests

9. Presence of severe chronic kidney disease

10. Diagnosis of amyloidosis at baseline.

Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Anakinra

    Anakinra, once daily s.c. injection, starting dose of 100 mg/day for patients with body weight ≥ 50 kg and 1-2 mg/kg/day for patients with body weight \< 50 kg for 6 months. For patients \< 16 years and \< 50 kg not responding sufficiently, the dose can be increased up to 4 mg/kg/day (max of 200 mg/day).

    Drug: Anakinra

Interventions

  • Subcutaneous injections once daily for 6 months

    Also known as: Kineret

06

What researchers measure

Primary outcomes

  1. Change from baseline in the number of FMF attacks per month.

    An FMF attack is defined as fever ≥ 38°C lasting between 6 hours to 7 days and accompanied by painful serositis manifestations in any of the following sites: abdomen, chest, joints and skin.

    Time frame: Up to 6 Months

Secondary outcomes

  1. The number of months free of FMF attacks will be evaluated in each patient.

    An FMF attack is defined as fever ≥ 38°C lasting between 6 hours to 7 days and accompanied by painful serositis manifestations in any of the following sites: abdomen, chest, joints and skin.

    Time frame: Up to 6 months.

  2. Change from baseline in C-reactive protein (CRP) concentrations.

    CRP levels (measured in mg/L) will be determined in serum.

    Time frame: Up to 6 months.

  3. Change from baseline in Serum Amyloid A (SAA) concentrations.

    SAA levels (measured in mg/L) will be determined in serum.

    Time frame: Up to 6 months.

  4. Change from baseline in the dose of analgesic agents used for the treatment of FMF symptoms.

    Reduction in the dose (measured in mg/kg) of analgesic treatments for FMF attacks will be evaluated during the study.

    Time frame: Up to 6 months.

  5. Number of patients responding to study drug over time using the Modified FMF50 score.

    Modified FMF50 score response is defined by the to the presence of 3 of the 4 following criteria: decrease by ≥ 50% in the frequency of all FMF attacks; decrease by ≥ 50% in the frequency of FMF attacks in the joints; decrease by ≥ 50% in the levels of either SAA or CRP (measured as mg/L) with target level concentrations for CRP and SAA ≤10 mg/L; Increase by ≥ 50% in QoL values assessed using the VAS scale (0-10cm), where scores of 0 and 10 indicate the lowest and highest QoL scores, respectively.

    Time frame: Up to 6 months.

  6. Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs), deaths, and AEs leading to study drug discontinuation

    An AE is any untoward medical occurrence in a study patient to whom a medicinal product is administered, and which does not necessarily have a causal relationship with this treatment. AEs include abnormal test findings, clinically significant signs and symptoms, changes in physical examination findings, progression or worsening of underlying disease. Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards.

    Time frame: Up to 7 months

  7. Changes over time in vital signs

    Vital signs change of each patients are evaluated over time. The vital sign evaluated are blood pressure (mmHg), heart rate (beats per minute), and body temperature (Celsius degrees).

    Time frame: Up to 7 months

  8. Changes over time in body weight and height

    Body weight (kilograms) and height (centimeters) of each patients are evaluated over time.

    Time frame: Up to 7 months

  9. Changes over time in Laboratory safety assessment

    Number of patients with abnormal laboratory test results

    Time frame: Up to 7 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Aug 2027, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2024
First posted
Oct 30, 2024
StartEst.
Mar 1, 2026
Primary completionEst.
Aug 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06666335
Collaborators
Tigermed Consulting Co., Ltd
Responsible party
Sponsor
First posted
Oct 30, 2024
Start date
Mar 1, 2026 (estimated)
Primary completion
Aug 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Jun 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interleukin 1 Receptor Antagonist Protein

Start the discussion